PharmaVitae explores Lundbeck’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
Publisher: Datamonitor Healthcare
Published: 25 January 2021
Number of pages:39
Lundbeck is a leader in the psychiatric and neurological disorder market, with more than $2.5 billion in revenue in 2019.
Lundbeck experienced a strong growth of 28% in sales of its strategic products – Abilify Maintena, Trintellix, Northera, and Rexulti in 2019, which represented 55% of its total revenue.
Lundbeck’s prescription pharmaceutical sales are forecast to grow over the forecast period, driven by the continued growth of its four strategic brands Abilify Maintena, Trintellix, Northera, and Rexulti.
Rexulti is expected to add a significant amount of sales over the forecast period, adding over $1 billion by 2025.
Lundbeck is expected to generate most of its revenue from the Central Nervous System (CNS) therapy area as the company focuses on developing new medicines within a number of indications for the treatment of brain diseases.
Launch of Rexulti in European countries will contribute significantly to Lundbeck’s revenue growth in the years to come. The product is being branded as Rxulti in countries within the European Union.
Lundbeck will see revenue loss due to the impact from the generic erosion of products such as Onfi and Sabril.
Lundbeck’s strategic brands, Rexulti and Trintellix, will continue to grow in the US due to solid underlying demand.
International Markets are expected to show growth driven by sales in Australia, Brazil, China, Japan and South Korea.
High-impact upcoming events comprise topline Phase IIIb trial results and an expected CHMP opinion for Vyepti.
In October 2019, Lundbeck completed the acquisition of Alder BioPharmaceuticals (which has subsequently been renamed Lundbeck Seattle BioPharmaceuticals, Inc.) for an aggregate cash consideration of up to approximately $1.95 billion (DKK13 billion) net of cash, on a fully diluted basis.
PharmaVitae explores Lundbeck’s prescription pharmaceutical performance and outlook over 2019–29.
Overview – Lundbeck’s prescription pharmaceutical sales are set to grow over the forecast period.
Key themes –  Key CNS products are expected to drive continued growth  Generic market entries will erode sales of five drugs  Acquisition of Alder BioPharmaceuticals adds Vyepti to Lundbeck’s product portfolio.
Model updates (4 November 2020)
Cipralex forecast adjusted higher in Rest of World
Onfi forecast adjusted higher due to better-than-expected performance given generic competition
Trintellix forecast adjusted lower in Europe.
Model updates (13 August 2020)
Rexulti forecast adjusted higher due to continued strong uptake in the US across schizophrenia and major depressive disorder.
Rexulti forecast adjusted lower in 5EU and Rest of World due to current trends as well as the discontinuation for bipolar disorder.
Model updates (12 May 2020)
Eptinezumab name changed to Vyepti.
Model updates (6 February 2020)
Eptinezumab added to forecast after acquisition of Alder BioPharmaceuticals for $1.95bn.
Table of Contents
Key Drug & Company Information
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726